Market research
NFX.LSE Nuformix plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4M
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 1.53
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BYW79Y38
- Market cap
- 4M
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 1.53
About
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NFX.LSE discussion.
5 years, 5 months ago
Nuformix plc is currently in a long term downtrend where the price is trading 21.2% below its 200 day moving average.
From a valuation standpoint, the stock is 87.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.5.
Nuformix plc's total revenue sank by 0.0% to $268K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-66K since the same quarter in the previous year.
Finally, its free cash flow fell by 209.4% to $-162K since the same quarter in the previous year.
Based on the above factors, Nuformix plc gets an overall score of 1/5.